Compare HP Inc (HPQ) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Heron Therapeutics Inc — how do they compare? HP Inc trades at $24.56 (market cap $22.15B), while Heron Therapeutics Inc trades at $0.46 (market cap $91.46M). The key difference: HP Inc is far larger — about 242.2× Heron Therapeutics Inc's market cap, and HP Inc pays a 4.95% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HPQ | HRTX | |
|---|---|---|
Market Cap | $22.15B | $91.46M |
Sector | Technology | Health |
52-Week High | $29.35 | $1.96 |
52-Week Low | $18.20 | $0.39 |
Enterprise Value | $29.31B | $189.36M |
Dividend Yield | 4.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $24.395, down 1.79% on the day, with a bullish technical setup showing strong moving average signals. The stock offers attractive valuation metrics including a P/E of 9.2 and P/S of 0.41, with consistent earnings beats in recent quarters. Recent developments include strategic partnerships with OpenAI and Ferrari, positioning the company for AI PC growth. Cash flow trends show improvement with 2025 net cash flow of $460 million, though revenue has declined from 2022's $63B to $55.3B in 2025.
HPQ presents a value opportunity with strong dividend yield and improving cash flows, but faces headwinds from PC market volatility and competitive pressures. Analyst sentiment is mixed with 29% buy ratings versus 55% hold, suggesting cautious optimism. The stock's near-term performance will depend on AI PC adoption and execution of new strategic partnerships.
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
